Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model

Melanie T Cushion, PhD MS, Alan Ashbaugh, Voon Ong, PhD

Blood (2019) 134 (Supplement_1): 3266.

https://doi.org/10.1182/blood-2019-127392

Published: 2019

Journal Articles

Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy

Jason N Barreto, PharmD, Carrie A. Thompson, MD, Kristin C. Mara, MS., Amanda G Sierzchulski, PharmD, Ashley L Potter, PharmD, Pritish K Tosh, MD, Andrew H Limper, MD

Blood (2019) 134 (Supplement_1): 4052.

https://doi.org/10.1182/blood-2019-122060

Published: 2019

Journal Articles

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Martin W. Schoen, MDMPH, Peter Georgantopoulos, MS, Nagasai S Yalavarthi, BS, Charles L. Bennett, MD PhD

Blood (2019) 134 (Supplement_1): 2135.

https://doi.org/10.1182/blood-2019-121770

Published: 2019

Journal Articles

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Louis-Bassett Porter, MD, Hanaa Shihadeh, Kim Dittus, MD PhD

Blood (2019) 134 (Supplement_1): 2116.

https://doi.org/10.1182/blood-2019-121534

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Blood (2018) 132 (Supplement 1): 683.

https://doi.org/10.1182/blood-2018-99-115241

Published: 2018

Journal Articles

Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?

Karan Jatwani, MBBS, Shraddha Jatwani, MBBS, MD, Sridevi Rajeeve, MD, Karan Chugh, MBBS, MD, Rakesh Kumar Sharma, MBBS, MD, Stuthi Perimbeti, MD MPH, Vivek Suresh Modi, MBBS, Siva Krishna Mannem, MBBS

Blood (2018) 132 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2018-99-120214

Published: 2018

Journal Articles

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

Elizabeth A Lakota, PharmD, MS, Shawn Flanagan, PhD, Taylor Sandison, MD, MPH, Janice W Brown, MD, Christopher M Rubino, Pharm.D.

Blood (2018) 132 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2018-99-110300

Published: 2018

Journal Articles

Pneumocystis Jiroveci Pneunomia Prophylaxis during Maintenance Therapy with Hyper-CVAD Regimens for Adult Acute Lymphoblastic Leukemia

Grace A. Martin, PharmD, Shilpa Paul, PharmD, Wei Qiao, PhD, Elias J. Jabbour, MD, Dimitrios P. Kontoyiannis, MD, Deborah A. McCue, PharmD

Blood (2017) 130 (Supplement 1): 1295.

https://doi.org/10.1182/blood.V130.Suppl_1.1295.1295

Published: 2017

Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD

Blood (2017) 130 (Supplement 1): 819.

https://doi.org/10.1182/blood.V130.Suppl_1.819.819

Published: 2017

Journal Articles

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Mark T Drayson, MD PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Gulnaz Iqbal, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Peter Hawkey, FRCPath, Helen Higgins, MSc, Janet Dunn, PhD

Blood (2017) 130 (Supplement 1): 903.

https://doi.org/10.1182/blood.V130.Suppl_1.903.903

Published: 2017

Journal Articles

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Blood (2016) 128 (22): 2777.

https://doi.org/10.1182/blood.V128.22.2777.2777

Published: 2016

Journal Articles

Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis

Melanie Cushion, Alan Ashbaugh, Keeley Lynch, Michael J. Linke, Ken Bartizal, PhD

Blood (2016) 128 (22): 3396.

https://doi.org/10.1182/blood.V128.22.3396.3396

Published: 2016

Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Blood (2016) 128 (22): 1218.

https://doi.org/10.1182/blood.V128.22.1218.1218

Published: 2016

Journal Articles

Examining the Role of Bronchoscopy in Patients with Hematological Malignancies

Nakul Singhal, MD, Rashi Sharma, MD, Ashwin Chandar, MD, Vincent McAuliffe, MD, Dennis L Cooper, MD

Blood (2016) 128 (22): 2412.

https://doi.org/10.1182/blood.V128.22.2412.2412

Published: 2016

Journal Articles

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Jacqueline W. Mays, DDS, MHSc, PhD, Lauren M. Curtis, MD, Carol Bassim, DMD, MS, Seth M. Steinberg, PhD, David Venzon, PhD, Jeremy J. Rose, MS, Monica Cho, Christopher G. Kanakry, MD, Fahd Yazdanie, Daniele Avila, NP, Kristin Baird, MD, Jennifer Hsu, RN, Licia Masuch, George Grimes, RPh, Judith Starling, RPh, Daniel H. Fowler, MD, Ronald E. Gress, MD, Fran T. Hakim, PhD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 826.

https://doi.org/10.1182/blood.V128.22.826.826

Published: 2016

Journal Articles

Microtransplantation for Elderly Acute Myeloid Leukemia - Current and Future

Huisheng Ai, MD, Mei Guo, Kaixun Hu

Blood (2015) 126 (23): 4941.

https://doi.org/10.1182/blood.V126.23.4941.4941

Published: 2015

Journal Articles

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Harminder Paul, Susi Snitzler, RN, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B. Gibson, PhD, Michelle L. Queau, B.Sc, Suzanne Trudel, MD

Blood (2015) 126 (23): 4163.

https://doi.org/10.1182/blood.V126.23.4163.4163

Published: 2015

Journal Articles

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

Jeanette Lundin, MD PhD, Steven T. Rosen, MD, Anders Österborg, MDPhD, Olga Frankfurt, MD, Jane N. Winter, MD, Alfred Rademaker, Jennifer Kreutzer, Elizabeth Bacon, Sonja Sönnert-Husa, Shuo Ma, MD PhD

Blood (2015) 126 (23): 1734.

https://doi.org/10.1182/blood.V126.23.1734.1734

Published: 2015

Journal Articles

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

Clive S. Zent, MD, Betsy R LaPlant, MS, Wenting Wu, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Michael J. Conte, PA-C, George J. Weiner, MD, Thomas E Witzig, MD

Blood (2013) 122 (21): 1641.

https://doi.org/10.1182/blood.V122.21.1641.1641

Published: 2013

NARROW

Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model

Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

Pneumocystis Jiroveci Pneunomia Prophylaxis during Maintenance Therapy with Hyper-CVAD Regimens for Adult Acute Lymphoblastic Leukemia

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Examining the Role of Bronchoscopy in Patients with Hematological Malignancies

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Microtransplantation for Elderly Acute Myeloid Leukemia - Current and Future

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only